Valion Bio, Inc. (VBIO) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US8887053085
Valion Bio, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -7.90 m USD |
| EBIT | -8.76 m USD |
| Net income | -8.88 m USD |
Full history since 2010, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Valion Bio, Inc.
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
More stocks
- ESS Tech, Inc. (GWH)
- Onconetix, Inc. (ONCO)
- SmartKem, Inc. (SMTK)
- Livento Group, Inc. (LIVG)
- BURZYNSKI RESEARCH INSTITUTE INC (BZYR)
- Metavesco, Inc. (MVCO)
- ALKALINE WATER Co INC (WTER)
- Telvantis, Inc. (RDAR)
- ESPORTS ENTERTAINMENT GROUP, INC. (GMBLP)
- Wellchange Holdings Company Limited (WCT)
- Resonate Blends, Inc. (KOAN)
- Vicarious Surgical Inc. (RBOT)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.